Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Heart failure disease management program, its contribution to established pharmacotherapy and long-term prognosis in real clinical practice - retrospective data analysis

M. Lazarova, D. Lazar, F. Malek, J. Vaclavik, M. Taborsky, A. Ignaszewski,

. 2018 ; (4) : . [pub] 20181005

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19011733

BACKGROUND AND AIMS: The prognosis of patients with heart failure (HF) is still generally unfavorable. HF with reduced ejection fraction (HFrEF) patients reach target medication doses in very low percentages in daily clinical practice. HF disease management programs (DMP), including nurse and telemedicine support that facilitate achieving target medication doses, may improve the unfavorable prognosis. METHODS: We retrospectively analyzed the data of 738 patients with HFrEF who were followed in a single HF center during the years 1975-2011, for 6.4 (median) years. DMP, nurse and telemedicine support is established at this center. RESULTS: The group achieved left ventricle (LV) recovery after the HF treatment. The median LV ejection fraction improved from 25.0% at baseline to 50.0% at the time of the latest data collection. The proportion of NYHA II, III and IV classes decreased from 27.6%, 30.2% and 29.7% to 26.6%, 7.2% and 0.1%, respectively while the proportion of NYHA class I increased from 12.5% to 66.1%. Median NT-proBNP decreased from 975.0 to 324.0 pg/mL. The survival of the patient group was favorable; 79.7% survived 18.1 years after diagnosis of HF. A high percentage of the patients received recommended target or higher than target doses of angiotensin-converting enzyme inhibitors (82.0%) and beta-blockers (78.1%). CONCLUSION: The established pharmacotherapy resulted from an effective DMP and this contributed to the favorable prognosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19011733
003      
CZ-PrNML
005      
20190404093637.0
007      
ta
008      
190404s2018 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2018.059 $2 doi
035    __
$a (PubMed)30305762
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Lazarova, Marie $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
245    10
$a Heart failure disease management program, its contribution to established pharmacotherapy and long-term prognosis in real clinical practice - retrospective data analysis / $c M. Lazarova, D. Lazar, F. Malek, J. Vaclavik, M. Taborsky, A. Ignaszewski,
520    9_
$a BACKGROUND AND AIMS: The prognosis of patients with heart failure (HF) is still generally unfavorable. HF with reduced ejection fraction (HFrEF) patients reach target medication doses in very low percentages in daily clinical practice. HF disease management programs (DMP), including nurse and telemedicine support that facilitate achieving target medication doses, may improve the unfavorable prognosis. METHODS: We retrospectively analyzed the data of 738 patients with HFrEF who were followed in a single HF center during the years 1975-2011, for 6.4 (median) years. DMP, nurse and telemedicine support is established at this center. RESULTS: The group achieved left ventricle (LV) recovery after the HF treatment. The median LV ejection fraction improved from 25.0% at baseline to 50.0% at the time of the latest data collection. The proportion of NYHA II, III and IV classes decreased from 27.6%, 30.2% and 29.7% to 26.6%, 7.2% and 0.1%, respectively while the proportion of NYHA class I increased from 12.5% to 66.1%. Median NT-proBNP decreased from 975.0 to 324.0 pg/mL. The survival of the patient group was favorable; 79.7% survived 18.1 years after diagnosis of HF. A high percentage of the patients received recommended target or higher than target doses of angiotensin-converting enzyme inhibitors (82.0%) and beta-blockers (78.1%). CONCLUSION: The established pharmacotherapy resulted from an effective DMP and this contributed to the favorable prognosis.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lazar, Dusan $u Department of Biophysics, Faculty of Science, Palacky University Olomouc, Czech Republic.
700    1_
$a Malek, Filip $u Heart Failure Centre, Hospital Na Homolce, Prague, Czech Republic.
700    1_
$a Vaclavik, Jan $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
700    1_
$a Taborsky, Milos $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
700    1_
$a Ignaszewski, Andrew $u Department of Cardiology, Heart Function Clinics, St. Paul´s Hospital, Vancouver, Canada.
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g č. - (2018)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30305762 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y a $z 0
990    __
$a 20190404 $b ABA008
991    __
$a 20190404093645 $b ABA008
999    __
$a kom $b bmc $g 1390880 $s 1050038
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $c 4 $e 20181005 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$a Pubmed-20190404
Back

Find record

Citation metrics

Logged in users only

Archiving options